(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 October 2011 (20.10.2011)

PCT

(10) International Publication Number
WO 2011/129768 A1

(51) **International Patent Classification**:
G01N 33/68 (2006.01)

(21) **International Application Number**:
PCT/SG2011/000143

(22) **International Filing Date**:
12 April 2011 (12.04.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/322,949 12 April 2010 (12.04.2010) US

(71) **Applicant** *(for all designated States except US)*: **NATIONAL UNIVERSITY OF SINGAPORE** [SG/SG]; 21 Lower Kent Ridge Road, Singapore 119077 (SG).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **NG, Peng, Keat, Daniel** [SG/SG]; c/o National University of Singapore, Yong Loo Lin School of Medicine, Department of Epidemiology and Public Health, 21 Lower Kent Ridge Road, Singapore 119077 (SG). **TAI, Bee, Choo** [SG/SG]; c/o National University of Singapore, Yong Loo Lin School of Medicine, Department of Epidemiology and Public Health, 21 Lower Kent Ridge Road, Singapore 119077 (SG). **CHIA, Kee, Seng** [SG/SG]; c/o National University of Singapore, Yong Loo Lin School of Medicine, Department of Epidemiology and Public Health, 21 Lower Kent Ridge Road, Singapore 119077 (SG). **HOLTHOFER, Harry** [FI/FI]; c/o The Haartman Institute, Haartmaninkatu 3, PB 63, University of Helsinki, FIN-00014 Finland (FI).

(74) **Agent**: **AMICA LAW LLC**; 30 Raffles Place, #18-03/04 Chevron House, Singapore 048622 (SG).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2011/129768 A1

(54) **Title**: A BIOMARKER FOR RENAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES

(57) **Abstract**: The invention provides kits and methods for the diagnosis, prognosis, and treatment of reduced kidney function in patients, such as diabetic patients. The methods include a step of detecting one or more nephrin degradation products in a sample from the subject, such as a urine sample.

A BIOMARKER FOR RENAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES

RELATED APPLICATION

This application claims the benefit of U.S. Provisional Application No. 61/322,949, filed on April 12, 2010. The entire teachings of the above application are incorporated by reference.

BACKGROUND OF THE INVENTION

The renal glomerulus plays a critical role in the modulation of albuminuria and renal function. In addition to its role in congenital nephrotic syndrome of the Finnish type, the importance of the transmembrane protein nephrin (NPHS1) in modulating renal phenotypes is also evidenced in diabetes. In models of experimental diabetes, dysregulation of nephrin gene expression has been associated with albuminuriaThe dominant and traditional view of the natural history of diabetic nephropathy is that albuminuria precedes a decline in renal function but this has been subject to recent debate (Retnakaran et al. 2006). It has been variously reported that a decline in renal function (expressed as the glomerular filtration rate, GFR) may be evident even in the absence of albuminuria (MacIsaac et al. 2004). The involvement of nephrin in controlling renal function is unclear, however, with the literature largely emphasizing the role of this protein in altered renal parameters reflected as albuminuria.

In view of the importance of kidney function in maintaining homeostasis and the prevalence of disorders associated with an increased risk of reduced renal function, such as type 2 diabetes, a need exists for methods for the diagnosis, prognosis, and treatment of reduced kidney function, as well as kits for performing such methods.

SUMMARY OF THE INVENTION

The invention provides, inter alia, diagnostic and prognostic methods for detecting reduced renal function in a subject, as well as methods of treating a subject with reduced renal function and kits for performing any of these methods. The invention is based, at least in part, on the significant discovery that fragments of the nephrin protein are detectable in the urine of patients with type 2 diabetes are associated with reduced renal function and that the presence of one or more nephrin protein fragments are indicative of reduced renal function.

Accordingly, in one aspect, the invention provides methods of detecting reduced renal function in a mammalian subject by detecting one or more nephrin degradation products in a urine sample from the subject, where detection of one or more nephrin degradation products in the urine sample indicates reduced renal function in the subject. In particular embodiments, the subject is a human. In some embodiments, the subject is normoalbuminuric. In particular embodiments, the subject has or is at increased risk for developing type 2 diabetes (T2D). In more particular embodiments, the subject has been diagnosed with T2D for less than 1 year. In certain embodiments, the subject exhibits a decline in eGFR of at least 1.0 ml/min/1.73 m2.

In certain embodiments, the one or more nephrin degradation products has an apparent molecular weight of about 25 kDa, 50 kDa, 60 kDa, or 75 kDa and in more particular embodiments, an apparent molecular weight of about 25 kDa. The one or more nephrin degradation products can be detected by a variety of means including ELISA, Western Blotting, HPLC, SPR, SAT, aptamers, pepide sequencing, or MS/MS. In certain embodiments, the nephrin degradation products are detected using an antibody and in more particular embodiments, the antibody is a monoclonal antibody. In particular embodiments, the nephrin degradation products are detected in a cell free fraction of a urine sample.

In another aspect, the invention provides methods of treating reduced kidney function. For example, the treatment methods of the invention can

include the steps of any of the diagnostic methods provided by the invention with the further step(s) of administering a suitable prophylaxis for reduced renal function to the subject.

In yet another aspect, the invention provides kits for detecting reduced renal function in a mammal. The kits include can include any or all of the components for performing any of the methods provided by the invention. In some embodiments, the kits include an antibody that binds one or more nephrin degradation products. In more particular embodiments, the kit also includes instructions for use. In some embodiments, the kit includes one or more nephrin degradation products suitable for use as a positive control. In certain embodiments, the antibody in the kit is associated with an immunochromatographic device, such as a dip test.

The invention advantageously enables the skilled artisan to quickly and easily identify subjects with reduced renal function, including situations where the subject exhibits normal kidney function according to existing assays, such as albumin levels in the urine.

DETAILED DESCRIPTION OF THE INVENTION

The invention provides kits and methods for the diagnosis, prognosis, and treatment of reduced kidney function in patients, such as diabetic patients. The methods include a step of detecting one or more nephrin degradation products in a sample from the subject, such as a urine sample. A description of example embodiments of the invention follows.

Nephrin degradation products

Nephrin, the protein product of NPHS1, is a member of the immunoglobulin family of cell adhesion molecules that functions in the glomerular filtration barrier in the kidney. The gene is primarily expressed in renal tissues, and the protein is a type-1 transmembrane protein found at the slit diaphragm of glomerular podocytes. Nephrin genes have been identified in a variety of organisms, some of which are summarized in Table A, below.

Table A Nephrin genes

Organism	**GeneID**
Bos taurus	519706
Canis lupus familiaris	484571
Danio rerio	692352
Homo sapiens	4868
Mus musculus	54631
Oryctolagus cuniculus	100354996
Pan troglodytes	468841
Rattus norvegicus	64563
Xenopus laevis	734213

The gene identifiers in Table A may be used to retrieve, *inter alia*, publicly-available annotated mRNA or protein sequences from sources such as the NCBI website, which may be found at the following uniform resource locator (URL): http://www.ncbi.nlm.nih.gov. The information associated with these identifiers, including reference sequences and their associated annotations, are incorporated by reference. For example, the gene identifiers can be used to retrieve human, mouse, and rat nephrin protein reference sequences and associated annotations (such as structural domains), such as NP_004637 (SEQ ID NO: 1), NP_062332.2, and NP_062332.2, respectively. *See also*, HomoloGene: 20974, which provides multiple sequence alignment information for nephrin protein sequences from a variety of organisms. These sequence comparisons can be used to identify regions that are conserved between organisms and would therefore be expected to be important to the structure and/or function of nephrin proteins. Additional useful tools for converting IDs or obtaining additional information on a gene are known in the art and include, for example, DAVID, Clone/GeneID converter, and SNAD. *See* Huang et *al., Nature Protoc.* 4(1):44-57 (2009), Huang *et al., Nucleic Acids Res.* 37(1)1-13 (2009), Alibes *et al., BMC Bioinformatics* 8:9 (2007), Sidorov *et al., BMC Bioinformatics* 10:251 (2009).

"Nephrin degradation product(s)" are fragments of nephrin protein that correspond to fragments detectable in the urine of human subjects with reduced kidney function where the nephrin degradation products in human exhibit apparent molecular weights of 25, 50, 60 or 75 kDa on an SDS-PAGE Western Blot under reducing conditions. "Corresponds to" means an analogous sequence from another organism as determined by suitable means known in the art, such as sequence alignments. For example, a corresponding nephrin degradation product from a non-human animal may exhibit apparent molecular weights that are identical, highly similar (<=10% deviation—higher or lower— *e.g.*, 9, 8, 7, 6, 5, 4, 3, 2, 1%, or less), similar (10-20% deviation), or dissimilar (>20% deviation, *e.g.*, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100%, or more) to human. In certain embodiments, a nephrin degradation product includes a sequence at least 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99%, or more identical to a fragment of at least 5, 10, 12, 13, 14, 15, 16, 17, 18, 19, 20, 50, 100, 200, 400, 600, 800, or 1000 contiguous amino acids of SEQ ID NO: 1, the reference human nephrin protein sequence with NCBI accession number NP_004637, which is incorporated by reference in its entirety. For example, in particular embodiments, a nephrin degradation product may include an amino acid sequence that is at least 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99% identical to the sequence of human nephrin degradation products that exhibit apparent molecular weights of 25, 50, 60, or 75 kDa on an SDS-PAGE Western Blot under reducing conditions. These sequences may be determined using routine methods in the art, such as, for example, peptide sequencing of fractionated samples, *e.g.*, following Western Blotting or two or higher dimensional protein electrophoresis.

Programs for sequence alignments and comparisons include FASTA (Lipman and Pearson, *Science,* 227: 1435–41 (1985) and Lipman and Pearson, *PNAS,* 85: 2444–48), BLAST (McGinnis & Madden, *Nucleic Acids Res.*, 32:W20-W25 (2004) (current BLAST reference, describing, *inter alia*, MegaBlast); Zhang *et al.*, *J. Comput. Biol.,* 7(1-2):203-14 (2000) (describing the "greedy algorithm" implemented in MegaBlast); Altschul *et al.*, *J. Mol. Biol.*, 215:403-410 (1990) (original BLAST publication)), Needleman-

Wunsch (Needleman and Wunsch, *J. Molec. Bio.*, 48 (3): 443–53(1970)), Sellers (Sellers, *Bull. Math. Biol.*, 46:501-14 (1984), and Smith-Waterman (Smith and Waterman, *J. Molec. Bio.*, 147: 195–197 (1981)), and other algorithms (including those described in Gerhard *et al., Genome Res.*, 14(10b):2121-27 (2004)), which are incorporated by reference. In particular embodiments, sequences are compared by BLAST using default parameters for protein queries.

Subjects

Subjects to be diagnosed, prognosed, or treated by the methods and/or kits provided by the invention can be any mammal, such as a primate, a rodent, a canine, a feline, a porcine, an ovine, a bovine, or a leporine. In still more particular embodiments, the subject is a primate, *e.g.*, a human.

The subject may be male or female and at any stage of development, *e.g.*, a fetus, neonate, infant, child, adolescent, adult, or geriatric. In particular embodiments, the subject is a child, adolescent, adult, or geriatric. In still more particular embodiments, the subject is an adult or geriatric.

Subjects for the methods provided by the invention can be defined by a variety of clinical parameters. In particular embodiments, the subject may be at increased risk for or have diabetes, *e.g.*, type 1 (T1D) or type 2 (T2D) diabetes and in more particular embodiments, the subject has or is at increased risk for developing T2D, for example, a subject may be a borderline T2D subject, *e.g.*, impaired glucose tolerance or impaired fasting glycemia. A subject that has T2D, impaired fasting glucose, impaired glucose tolerance, can be defined according to the criteria in Table B:

Table B, where 2 hour glucose is 2 hours after ingestion of 75g oral glucose.

Condition	Test	Classifier
Diabetes	Fasting plasma glucose or 2–h plasma glucose or Causal plasma glucose or HbA1c	≥7.0mmol/l (126mg/dl) or ≥11.1mmol/l (200mg/dl) or ≥11.1mmol/l (200mg/dl) or ≥6.5%
Impaired glucose tolerance	2–h plasma glucose	≥7.8 and <11.1mmol/l (140mg/dl and 200mg/dl)
Impaired fasting glucose	Fasting plasma glucose	6.1 to 6.9mmol/l (110mg/dl to 125mg/dl) (WHO guideline) or 5.6 to 6.9mmol/l (100mg/dl to 125mg/dl) (ADA guideline)

Diabetic subjects may have had diabetes (T1D or T2D) for any period of time, such as at least 1, 6, or 12 months, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25 years, or more. In particular embodiments, the subject has been diagnosed as diabetic for less than 1 year, *e.g.*, less than 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 months. The subject may be normoalbuminuric or have varying levels of albuminuria. A "normoalbuminuric" subject, or subject with "normoalbuminuria" and the like, exhibits clinically normal levels of albumin protein in the urine, consistent with normal kidney function. Albuminuria status can be determined by any means known in the art and, in some embodiments, can be characterized by albumin creatine ratio (ACR). For example, in certain embodiments, a normoalbuminuric subject has an ACR of less than about 30mg/g, *e.g.*, less than 32, 30, 28, 26, 24, 22, 20, 10, 15, 10, 5 mg/g, or less. Subjects may have any level of kidney function, which may be measured by any means, such as blood urea nitrogen, glomular filtration rate, inulin assay, or estimated glomular filtration rate (eGFR). Kidney function may be at 100, 95, 90, 85, 80, 70, 60, 50, 40, 30, 20, 10%, or less, of normal levels as measured by any of these assays. A normal range for eGFR is 60 to 90 ml/min/1.73 m^2, although it may exceed 90 ml/min/1.73 m^2 in some

individuals. Accordingly, in some embodiments, a subject may exhibit reduced eGFR of at least 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 ml/min/1.73 m^2, or more. For example, in certain particular embodiments, a subject may exhibit an eGFR of less than 65, 64, 63, 62, 61, 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, 50, 45, 40, 35, 30 ml/min/1.73 m^2, or less. T2D subjects treated by the method provided by the invention may be concurrently, previously, or subsequently treated by methods for regulating T2D, such as, modified diet, or administration of insulin, metformin, sulfonylureas, nonsulfonylurea secretagogues, alpha glucosidase inhibitors, thiazolidinediones, or combinations thereof.

Suitable subjects can be at any body mass index (kg/m^2), *e.g.*, < 16 (severely underweight), 16-18.5 (underweight), 18.5-25 (normal), 25-30 (overweight), 30-35 (obese I), 35-40 (obese II) or >40 (obese III). In particular embodiments, the subject may have a BMI of >25. In certain embodiments, a subject may exhibit a waist to hip ratio (WHR) of about 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, or 1.00. In some embodiments, a subject may exhibit triglyceride levels of about 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, or 2.1 (mmol/L) or ln triglyceride levels of about -2, -3, -4, -5, -6, -7, -8, -9, -10, -11, -12, -13, or -14.

Subjects may have any combination of the above parameters. A subject tested by the methods provided by the invention may exhibit 0, 1, 2, 3 or 4 nephrin degradation products. In particular embodiments, a subject determined to have reduced kidney function by the methods provided by the invention exhibits at least 1, 2, 3 or 4 nephrin degradation products in a urine sample. In more particular embodiments, a human subject determined to have reduced kidney function by the methods of the invention exhibits, in a urine sample, at least one of the nephrin degradation products with apparent molecular weights of 25 kDa, 50 kDa, 60 kDa or 75, kDa on an SDS-PAGE Western Blot under reducing conditions.

Kits and methods

The methods provided by the invention include the step of detecting nephrin degradation products—determining the presence of nephrin degradation products indicates reduced renal function in a subject. Nephrin degradation products may be detected by any means of protein detection known in the art, including, for example, ELISA, Western Blotting, RIA (radioimmunoassay), nucleic acid-based or protein-based aptamer techniques, HPLC (high precision liquid chromatography), SPR (surface plasmon resonance), SAT (suspension array technology—including both immune-based, aptamer-based, or combination methods), direct peptide sequencing (such as Edman degradation sequencing), or mass spectrometry (such as MS/MS). In particular embodiments, nephrin degradation products are detected using an antibody that binds one or more nephrin degradation products. In still more particular embodiments, the antibody binds the sequence pedqlptepp sgisekteag seedrvrney e (SEQ ID NO: 2), which corresponds to a fusion of amino acids 1045-1056 and 1097-1115 of SEQ ID NO: 1. In other embodiments, the antibody binds to a sequence comprising an amino acid sequence at least 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, or 100% identical to SEQ ID NO: 2 or a fragment thereof that is at least 10, 12, 13, 15, 18, 19, 20, 25, or 30 amino acids in length. For example, in more particular embodiments, the antibody binds to a sequence that is at least 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, or 100% identical to amino acids 1 to 12 of SEQ ID NO: 2, while in other particular embodiments, the antibody binds to a sequence that is at least 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, or 100% identical to amino acids 13-31 of SEQ ID NO: 2. In certain embodiments, antibodies for use in the methods and kits provided by the invention bind any of the foregoing antigens with a Ka of greater than about $1.0x10^6$, $5.0x10^6$, $1.0x10^7$, $5.0x10^7$, $1.0x10^8$, $5.0x10^8$, $1.0x10^9$ M^{-1}, or more.

The term "antibody," as used herein, refers to any polypeptide comprising an antigen-binding site regardless of the source, species of origin, method of production, and characteristics. In particular embodiments, an antibody is an immunoglobulin or an antigen-binding fragment thereof. As a

non-limiting example, the term "antibody" includes human, orangutan, macaque, camel, mouse, rat, rabbit, goat, sheep, and chicken antibodies. The term includes but is not limited to polyclonal, monoclonal, monospecific, polyspecific, non-specific, humanized, camelized, single-chain, chimeric, synthetic, recombinant, hybrid, mutated, and CDR-grafted antibodies. For the purposes of the present invention, it also includes, unless otherwise stated, antibody fragments such as Fab, F(ab')2, Fv, scFv, Fd, dAb, VHH (also referred to as nanobodies), and other antibody fragments that retain the antigen-binding function. Antibodies also include antigen-binding molecules that are not based on immunoglobulins, as further described below.

Antibodies to nephrin can be made, for example, via traditional hybridoma techniques (Kohler and Milstein, *Nature* 256: 495-499 (1975)), recombinant DNA methods (U.S. Patent No. 4,816,567), or phage display techniques using antibody libraries (Clackson *et al.*, *Nature* 352: 624-628 (1991); Marks *et al., J. Mol. Biol.* 222: 581-597 (1991)). For various other antibody production techniques, *see Antibodies: A Laboratory Manual*, eds. Harlow *et al.*, Cold Spring Harbor Laboratory, 1988.

In some embodiments, the term "antibody" includes an antigen-binding molecule based on a scaffold other than an immunoglobulin. For example, non-immunoglobulin scaffolds known in the art include small modular immunopharmaceuticals (*see, e.g.*, U.S. Patent Application Publication Nos. 2008/0181892 and 2008/0227958 published July 31, 2008 and September 18, 2008, respectively), tetranectins, fibronectin domains (*e.g.*, AdNectins, *see* U.S. Patent Application Publication No. 2007/0082365, published April 12, 2007), protein A, lipocalins (*see, e.g.*, U.S. Patent No. 7,118,915), ankyrin repeats, and thioredoxin. Molecules based on non-immunoglobulin scaffolds are generally produced by *in vitro* selection of libraries by phage display (*see, e.g.*, Hoogenboom, *Method Mol. Biol.* 178:1-37 (2002)), ribosome display (*see, e.g.*, Hanes *et al.*, *FEBS Lett.* 450:105-110 (1999) and He and Taussig, *J. Immunol. Methods* 297:73-82 (2005)), or other techniques known in the art (*see also* Binz *et al.*, *Nat. Biotech.* 23:1257-68 (2005); Rothe *et al.*, *FASEB J.* 20:1599-1610 (2006); and U.S. Patent Nos.

7,270,950; 6,518,018; and 6,281,344) to identify high-affinity binding sequences.

In particular embodiments, the methods of the invention include the step of detecting nephrin degradation products in a sample from a subject by Western Blot using a nephrin antibody that recognizes nephrin degradation products. The sample from the subject may be, for example, a blood or urine sample, and in particular embodiments is a urine sample. The sample may be prepared by any means suitable for the particular detection method employed. For example, in particular embodiments, a urine sample may be precipitated, for example, with trichloroacetic acid, centrifuged, optionally washed, and then resuspended in a suitable volume of buffer, such as Laemmli, before analysis. Pre-analysis may also include heating, for example, at about 60, 70, 80, 90, or 95°C for a sufficient period of time, *e.g.*, about 1, 2, 3, 4, 5, 10, 15, or more minutes. In particular embodiments, a urine sample to be analyzed by the methods provided by the invention is provided in a volume sufficient to contain at least 10, 15, 20, 25, 30, 35 μg, or more, of protein. In particular embodiments, the urine sample provides approximately 30 μg of protein. In certain particular embodiment, a urine sample may be processed before precipitation, *e.g.*, the sample is briefly centrifuged to produce a substantially cell-free sample for analysis. The sample may be frozen for later analysis or processed immediately.

Treatment methods provided by the invention may include the steps of any of the diagnostic methods described in the application and further include the step of providing a suitable prophylaxis to a subject found to have reduced kidney function. Suitable prophylaxis for reduced kidney function are known in the art and include, modified diet, modified activity schedule, modified fluid intake, modified osmolyte (*e.g.*, salt) intake (*e.g.*, a reduction of 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 95% or more of the USRDA of salt intake), administering antagonists of the renin-angiotensin system (RAS) /renin-angiotensin-aldosterone system (RAAS) pathway, dialysis, kidney transplant, or any combination of the foregoing.

Examples of RAS pathway antagonists are known in the art and include inhibitors of various components of the RAS pathway, including *e.g.*, antibodies or vaccines, dominant negative proteins, aptamers, and small molecule antagonists of RAS pathway components, including combinations thereof. Components of the RAS pathway and specific inhibitors are known and include renin inhibitors (*e.g.*, aliskiren, remikiren, and enalkiren), ACE (angiotensin-converting enzyme) inhibitors (*e.g.*, benazepril, captopril, enalapril, fosinopril, imidapril, lisinopril, perindopril, quinapril and ramipril, zofenopril, as well as casokinins, lactokinins and lactopeptides, such as Val-Pro-Pro or Ile-Pro-Pro), inhibitors of angiotensin II signaling (*e.g.*, antagonists of its receptors; particular AngII receptor antagonists include azilsartan, candesartan, eprosartan, exp 3174, irbesartan, losartan, olmesartan, telmisartan, and valsartan). In more particular embodiments RAS-pathway inhibitors can prevent formation of renal fibrosis. In some embodiments, renal fibrosis can be prevented or ameliorated by additional method known in the art, such as antagonism of TGF-β activity, for example, by small molecules, antibodies, or receptor decoys, such as receptor-Fc fusions.

The kits provided by the invention may include some or all of the components needed to perform any of the methods of the invention. For example, in certain embodiments, a kit includes a nephrin antibody that recognizes nephrin degradation products. The kit may include further elements, such as instructions for use, and/or suitable controls, such as one or more nephrin degradation products. In certain embodiments, the antibody in the kit is associated with a specialized device, such as a dip test lateral flow device (*e.g.*, an immunochromatographic device), as well as immunomagnetic devices and non-immune-based devices, such as aptamer or small-molecule based devices. In particular embodiments, the devices provided in the kits may be one-time use devices.

It should be understood that for all numerical bounds describing some parameter in this application, such as “about,” "at least," "less than," and "more than," the description also necessarily encompasses any range bounded by the recited values. Accordingly, for example, the description at least 1, 2,

3, 4, or 5 also describes, *inter alia*, the ranges 1-2, 1-3, 1-4, 1-5, 2-3, 2-4, 2-5, 3-4, 3-5, and 4-5, *et cetera*.

For all patents, applications, or other reference cited herein, such as non-patent literature and reference sequence information, it should be understood that it is incorporated by reference in its entirety for all purposes as well as for the proposition that is recited. Where any conflict exits between a document incorporated by reference and the present application, this application will control. All information associated with reference gene sequences disclosed in this application, such as GeneIDs or accession numbers, including, for example, genomic loci, genomic sequences, functional annotations, allelic variants, and reference mRNA (including, *e.g.*, exon boundaries or response elements) and protein sequences (such as conserved domain structures and/or mature regions of a preprotein) are hereby incorporated by reference in their entirety.

EXEMPLIFICATION

MATERIALS AND METHODS

Patients and urine samples

This study was conducted on 381 Chinese patients with type 2 diabetes who were recruited as part of the Singapore Diabetes Cohort Study (SDCS) (Unoki et al 2008, Ng et al 2008). Mid-stream spot urine samples were collected and transported chilled to the laboratory, centrifuged and stored at -80 °C prior to analysis. Albuminuria was determined on the basis of ACRs (mg/g) using commercially available kits for albumin and creatinine measurements (Exocell, Philadelphia, PA). Renal function (expressed as GFR) was estimated using the simplified Modification of Diet in Renal Disease (MDRD) equation where the estimated GFR (eGFR, ml/min/1.73 m^2) = 186.3 × (plasma creatinine in mg/dL)$^{-1.154}$ × (age in years)$^{-0.203}$ × (0.742 for women) × (1.21 if subject is black) [NKF 2002].

Nephrin analysis and Western blotting

For nephrin analysis, urine sample volumes corresponding to a total protein quantity of 30ug were precipitated with 10% (wt/vol) trichloroacetic acid in PBS on ice for 30 min. Thereafter the samples were centrifuged for 10

min at 13000g at +4°C and the precipitate washed in ice-cold acetone. The samples were then air-dried and dissolved in Laemmli buffer (62.5 mmol/l Tris-HCl , 10% glycerol, 2% SDS, 5% 2-mercaptoethanol and 0.05% bromophenol blue) and heated at 95 °C for 5 min. The samples were analyzed in 10% polyacrylamide gels with the Protean Mini-gel electrophoresis system using ready gels (Biorad Laboratories, Hercules, CA). A nephrinuric urine sample from a patient with type I diabetes was used as positive control in every gel. After electrophoresis, the proteins were transferred onto nitrocellulose filters (Amersham Biosciences, Buckinhamshire, UK) and blocked for 2 hours at room temperature with 3% non-fat dried milk (Valio, Helsinki, Finland) in PBS. Thereafter the filters were soaked in primary anti-nephrin antibody in PBS containing 1% milk as above and 0.02% sodium azide at room tempertaure, followed by thorough washes in PBS containing 0.2% Tween 20. The filters were then incubated with horseradish peroxidase-labeled second antibodies for one hour at room temperature and washed as above. The bound antibody was detected with Super Signal ECL substrate (Pierce, Rockford, IL). The presence of protein bands with the antibody staining was regarded as positive for nephrinuria. The typical prominent bands were detected at 25, 50, 60 and 75kDa areas with variable intensities and individual expression patterns as compared with the standards ladder.

Statistical analysis

The Student's *t*-test was used to compare differences in means between two groups of interest. For skewed data, the non-parametric equivalent based on the Wilcoxon rank sum test was used instead. The associations between the presence of immuno-reactive nephrin fragments in urine samples were evaluated using the Pearson's χ^2 test. To investigate whether there is any association between nephrinuria and renal function, while taking albuminuric status into account, multiple linear regression analysis was implemented. Log transformation was carried out on skewed data such ACR, triglycerides and diabetes duration prior to the multiple linear regression analysis. The regression analyses were adjusted for potential confounders such as log triglycerides, waist hip ratio and age, where appropriate. All statistical

evaluations were assessed based on a two-sided test at the conventional 5% level using STATA (version 10).

RESULTS

The main clinical characteristics of the 381 patients are presented as stratified by gender (Table 1). Males have larger WHR (P<0.001), lower levels of both LDL (P =0.002) and HDL cholesterol (P < 0.001) compared to females. Western blot analysis of the urine samples using a monoclonal antibody against human nephrin revealed the presence of up to four distinct protein bands with approximate molecular weights of 25, 50, 60, and 75 kDa. The most prevalent fragment was that with a molecular weight of 60 kDa which occurred in 155 of 381 samples (40.7%). This was followed by the fragments at 50 kDa (130/381, 34.1%), 25 kDa (88/381, 23.1%), and lastly, 75 kDa (59/381, 15.4%). The presence of these fragments was highly correlated with each other as seen in cross-tabulations (P < 0.001 for all comparisons) (Supplementary Table 1).

In multivariate analyses, the presence of each of the four fragments was associated with a decline in eGFR (largest P-value = 0.003) (Table 2). Logarithmic form of ACR (ln ACR) did not emerge as a significant independent predictor of eGFR (Model 1 in Tables 2). Even with the deliberate retention of ln ACR (Model 2 in Table 2), the presence of either the 25, 50 and 60 kDa fragments remained significantly associated with a loss of eGFR (all P values < 0.05). The exception was the 75 kDa fragment which while showing a trend towards a loss of eGFR, did not reach statistical significance (Table 2). Inclusion of ln ACR did not improve the overall fit of the regression model in predicting eGFR based on R^2 values (Table 2). The association of a lower eGFR with nephrinuria therefore was not confounded by the albuminuric status. WHR and ln triglyeride levels emerged as significant covariates. Age was expectedly associated with eGFR since it was used in the MDRD equation for the computing this variable (Table 2).

Among the four, the 25 kDa fragment was the strongest predictor of eGFR especially after adjustment for ln ACR (Tables 2). The presence of this fragment was associated with a loss in eGFR of 6.55 ml/min/1.73 m^2 (95%

confidence interval: 0.07 to 13.03). Stratifying the patient samples according to the presence of the 25 kDa fragment did not reveal any significant differences in clinical characteristics except for eGFR which was consistent with the multivariate analysis. Diabetes duration and WHR were greater in the presence of the 25 kDa fragment but these were only of borderline significance (Supplementary Table 2).

We next sought to characterize the potential association of nephrinuria with eGFR among 228 patients with normoalbuminuria as defined as having an ACR <= 30 mg/g. In multivariate analyses, nephrinuria with the exception of the 75 kDa fragment was significantly associated with a loss of eGFR (Table 3). Particularly, the presence of the 25 kDa fragment was associated with a loss in eGFR of 17.29 (95%CI: 6.56 to 28.01) ml/min/1.73 m^2 after adjustment for ln ACR (P = 0.002) (Table 3). ln triglycerides and WHR emerged as significant independent predictors of eGFR (Tables 3). Stratifying the patient samples according to the presence of the 25 kDa fragment among the normoalbuminuric patients did not reveal any significant differences in clinical characteristics except for eGFR. ACR was slightly higher in the presence of the 25 kDa fragment but this did not reach formal statistical significance (P = 0.077) (Supplementary Table 3).

DISCUSSION

In our current study, 5.3% of normoalbuminuric patients with type 2 diabetes showed evidence of nephrinuria as based on the presence of the 25 kDa fragment. Our study has also provided clinical information that supports this novel role of nephrin in modulating renal function. This positive finding was not only independent of albuminuria, but notably, it gained further statistical strength when the study was confined to normoalbuminuric diabetic patients.

Our finding has raised an intriguing biological question as to whether there is already early damage to the SD even in these normoalbuminuric patients. Our results clearly show that a subset of these patients present with both nephrin fragments and albumin early on during their disease course as measurable in the urine. For However, subsequent uptake of albumin at the

proximal tubules by the specific endocytotic mechanism employing the megalin-cubulin protein complex could have delayed the clinical appearance of microalbuminuria. Consistent with this notion, a recent proteomic study reported that enhanced excretion of megalin and cubulin in the urine (possibly reflecting damage to the proximal tubular uptake mechanism) was associated with the appearance of microalbuminuria in type 1 diabetic patients (Thrailkill 2009). In contrast to albumin reabsorption, it is much less clear whether nephrin fragments that have been shed into the urinary space early on could be actively taken up at the proximal tubules.

It would seem plausible that early damage to the podocytes, as indicated by nephrinuria, could potentially impact glomerular filtration. In conclusion, nephrinuria may provide new clinical insights into renal biology in diabetes even in normoalbuminuric patients who have traditionally been perceived as having a low risk of chronic kidney disease.

REFERENCES

1) Retnakaran *et al.*, *Diabetes* 55, 1832-1839, 2006
2) MacIsaac *et al.*, *Diabetes Care* 27, 195-200, 2004
3) National Kidney Foundation (NKF 2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis*, 39, S1–266, 2002
4) Ng *et al.*, *Diabetologia*, 51, 2318-2324, 2008
5) Unoki *et al.*, *Nature Genetics*, 40, 1098 – 1102, 2008
6) Thrailkill *et al.*, *Diabetes Care*, 32, 1266-1268, 2009

Table 1. Characteristics of Chinese Type 2 diabetic patients according to gender

	Total (n = 381)	Male (n = 183)	Female (n = 198)	*p*-value
Age, year	65.7 (9.3)	65.3 (9.30)	66.1 (9.35)	0.445
Diabetes duration, yr	6 (2 – 15)	6 (2 – 15)	5.5 (3 – 15)	0.947
BMI, kg/m^2	25.64 (4.36)	25.70 (4.40)	25.59 (4.34)	0.801
WHR	0.91 (0.07)	0.95 (0.06)	0.88 (0.05)	< 0.001
HbA1c, %	7.19 (0.99)	7.28 (0.99)	7.11 (1.00)	0.107
Systolic BP, mmHg	132.6 (12.15)	132.0 (12.58)	133.2 (11.67)	0.334
Diastolic BP, mmHg	78.4 (6.70)	78.8 (6.85)	78.0 (6.54)	0.287
Triglycerides, mmol/L	1.3 (1.0 – 1.9)	1.3 (0.9 – 1.8)	1.4 (1.0 – 2)	0.272
LDL cholesterol, mmol/L	3.05 (0.88)	2.91 (0.90)	3.20 (0.85)	0.002
HDL cholesterol, mmol/L	1.23 (0.35)	1.10 (0.31)	1.36 (0.35)	< 0.001
ACR, mg/g	22 (8.9 – 61.2)	19.4 (8.2 –58.1)	23.6 (10.1 – 64.4)	0.281
eGFR, ml/min/1.73 m^2	81.9 (25.2)	79.7 (23.88)	84.3 (26.4)	0.083

5 Data are presented as mean (SD) or median (interquartile range).

Table 2: Association of eGFR with the presence of individual immuno-reactive nephrin fragments in 381 Chinese diabetic patients

	Model 1 (without ln ACR)	Estimate (95% CI)	Standardized estimate	P-value	R^2
25 kDa fragment	25 kDa fragment	-8.84 (-14.05 to -3.63)	-0.148	0.001	32.12
	ln triglycerides	-8.33 (-12.52 to -4.14)	-0.175	< 0.001	
	WHR	-59.80 (-93.33 to -26.27)	-0.158	< 0.001	
	Age	-1.28 (-1.53 to -1.04)	-0.458	< 0.001	
	Model 2 (including ln ACR)				
	25 kDa fragment	-6.55 (-13.03 to -0.07)	-0.110	0.047	31.42
	ln ACR	-0.96 (-2.60 to 0.67)	-0.065	0.245	
	ln triglycerides	-8.06 (-12.27 to -3.85)	-0.169	< 0.001	
	WHR	-59.18 (-92.71 to -25.66)	-0.156	0.001	
	Age	-1.27 (-1.52 to -1.03)	-0.455	< 0.001	
	Model 1 (without ln ACR)	Estimate (95% CI)	Standardized estimate	P-value	R^2
50 kDa fragment	50 kDa fragment	-7.63 (-12.22 to -3.03)	-0.144	0.001	32.03
	ln triglycerides	-8.26 (-12.46 to -4.07)	-0.173	< 0.001	
	WHR	-63.37 (-96.79 to -29.96)	-0.167	< 0.001	
	Age	-1.31 (-1.55 to -1.06)	-0.466	< 0.001	
	Model 2 (including ln ACR)				
	50 kDa fragment	-5.67 (-10.87 to -0.48)	-0.107	0.032	32.50
	ln ACR	-1.19 (-2.67 to 0.30)	-0.080	0.116	
	ln triglycerides	-7.94 (-12.15 to -3.74)	-0.167	< 0.001	
	WHR	-61.36 (-94.80 to -27.92)	-0.162	< 0.001	
	Age	-1.29 (-1.53 to -1.04)	-0.459	< 0.001	

	Model 1 (without ln ACR)	Estimate (95% CI)	Standardized estimate	P-value	R^2
60 kDa fragment	60 kDa fragment	-7.53 (-12.03 to -3.03)	-0.148	0.001	32.06
	ln triglycerides	-7.59 (-11.81 to -3.37)	-0.159	< 0.001	
	WHR	-63.58 (-96.98 to -30.17)	-0.167	< 0.001	
	Age	-1.27 (-1.51 to -1.02)	-0.452	< 0.001	
	Model 2 (including ln ACR)				
	60 kDa fragment	-5.54 (-10.86 to -0.21)	-0.109	0.042	32.42
	ln ACR	-1.08 (-2.63 to 0.47)	-0.072	0.172	
	ln triglycerides	-7.48 (-11.69 to -3.26)	-0.157	0.001	
	WHR	-61.75 (-95.21 to -28.28)	-0.163	< 0.001	
	Age	-1.26 (-1.50 to -1.01)	-0.449	< 0.001	
	Model 1 (without ln ACR)	Estimate (95% CI)	Standardised estimate	P-value	R^2
75 kDa fragment	75 kDa fragment	-9.11 (-15.18 to -3.04)	-0.132	0.003	31.66
	ln triglycerides	-7.76 (-11.99 to -3.54)	-0.163	< 0.001	
	WHR	-63.21 (-96.72 to -29.70)	-0.166	< 0.001	
	Age	-1.29 (-1.54 to -1.05)	-0.461	< 0.001	
	Model 2 (including ln ACR)				
	75 kDa fragment	-5.74 (-13.47 to 1.99)	-0.083	0.145	32.03
	ln ACR	-1.18 (-2.85 to 0.50)	-0.079	0.168	
	ln triglycerides	-7.64 (-11.87 to -3.42)	-0.160	< 0.001	
	WHR	-61.49 (-95.05 to -27.93)	-0.162	< 0.001	
	Age	-1.28 (-1.52 to -1.04)	-0.457	< 0.001	

Table 3. Association of eGFR with the presence of individual immuno-reactive nephrin fragments among 228 patients with normoalbuminuria (ACR <= 30 mg/g)

	Model 1 (without ln ACR)	Estimate (95% CI)	Standardized estimate	p-value	R^2
25 kDa fragment	25 kDa fragment	-16.58 (-27.31 to -5.86)	-0.164	0.003	41.65
	ln triglycerides	-7.80 (-12.63 to -2.98)	-0.172	0.002	
	WHR	-75.78 (-111.97 to -39.59)	-0.221	< 0.001	
	Age	-1.32 (-1.58 to -1.06)	-0.532	< 0.001	
	Model 2 (including ln ACR)				
	25 kDa fragment	-17.29 (-28.01 to -6.56)	-0.171	0.002	42.31
	ln ACR	2.62 (-0.74 to 5.97)	0.082	0.126	
	ln triglycerides	-7.67 (-12.49 to -2.86)	-0.169	0.002	
	WHR	-75.59 (-111.66 to -39.52)	-0.221	< 0.001	
	Age	-1.34 (-1.60 to -1.08)	-0.540	< 0.001	
	Model 1 (without ln ACR)	Estimate (95% CI)	Standardized estimate	p-value	R^2
50 kDa fragment	50 kDa fragment	-5.72 (-11.75 to -0.32)	-0.100	0.064	40.04
	ln triglycerides	-7.14 (-12.00 to -2.28)	-0.157	0.004	
	WHR	-79.58 (-116.27 to -42.89)	-0.232	< 0.001	
	Age	-1.36 (-1.62 to -1.09)	-0.547	< 0.001	
	Model 2 (including ln ACR)				
	50 kDa fragment	-6.22 (-12.28 to -0.16)	-0.109	0.044	40.67
	ln ACR	2.55 (-0.86 to 5.97)	0.080	0.142	
	ln triglycerides	-7.00 (-11.85 to -2.14)	-0.154	0.005	
	WHR	-79.63 (-116.22 to -43.04)	-0.232	< 0.001	
	Age	-1.38 (-1.64 to -1.11)	-0.555	< 0.001	

	Model 1 (without ln ACR)	Estimate (95% CI)	Standardized estimate	p-value	R^2
60 kDa fragment	60 kDa fragment	-7.50 (-13.30 to -1.69)	-0.137	0.012	40.88
	ln triglycerides	-6.38 (-11.22 to -1.54)	-0.141	0.010	
	WHR	-79.13 (-115.54 to -42.72)	-0.231	< 0.001	
	Age	-1.31 (-1.58 to -1.05)	-0.530	< 0.001	
	Model 2 (including ln ACR)				
	60 kDa fragment	-8.49 (-14.37 to -2.61)	-0.156	0.005	41.77
	ln ACR	3.09 (-0.33 to 6.51)	0.097	0.076	
	ln triglycerides	-6.12 (-10.94 to -1.29)	-0.135	0.013	
	WHR	-79.17 (-115.38 to -42.95)	-0.231	< 0.001	
	Age	-1.33 (-1.59 to -1.07)	-0.537	< 0.001	
	Model 1 (without ln ACR)	Estimate (95% CI)	Standardized estimate	p-value	R^2
75 kDa fragment	75 kDa fragment	3.54 (-14.28 to 21.37)	0.021	0.696	39.08
	ln triglycerides	-6.93 (-11.82 to -2.03)	-0.153	0.006	
	WHR	-78.71 (-115.81 to -41.61)	-0.230	< 0.001	
	Age	-1.36 (-1.63 to -1.10)	-0.551	< 0.001	
	Model 2 (including ln ACR)	Estimate (95% CI)	Standardized estimate	p-value	R^2
	75 kDa fragment	-2.40 (-15.50 to 20.30)	-0.015	0.792	39.51
	ln ACR	-2.12 (-1.33 to 5.56)	-0.066	0.227	
	ln triglycerides	-6.79 (-11.68 to -1.89)	-0.149	0.007	
	WHR	-78.42 (-115.49 to -41.36)	-0.229	< 0.001	
	Age	-1.38 (-1.65 to -1.11)	-0.557	< 0.001	

5

Supplementary Table 1. Association between the presence of the immuno-reactive nephrin fragments in urine samples of type 2 diabetic patients (all P <0.0001)

		25 kDa fragment		
		N	Y	Total
50 kDa fragment	N	240	11	251
	Y	53	77	130
	Total	293	88	381

		25 kDa fragment		
		N	Y	Total
60 kDa fragment	N	220	6	226
	Y	73	82	155
	Total	293	88	381

		25 kDa fragment		
		N	Y	Total
75 kDa fragment	N	285	37	322
	Y	8	51	59
	Total	293	88	381

		50 kDa fragment		
		N	Y	Total
60 kDa fragment	N	207	19	226
	Y	44	111	155
	Total	251	130	381

		50 kDa fragment		
		N	Y	Total
75 kDa fragment	N	250	72	322
	Y	1	58	59
	Total	251	130	381

		60 kDa fragment		
		N	Y	Total
75 kDa fragment	N	226	96	322
	Y	0	59	59
	Total	226	155	381

Supplementary Table 2. Characteristics of Chinese Type 2 diabetic patients according to the urinary presence of the 25 kDa immuno-reactive nephrin fragment

		Total (n = 381)	Yes (n = 88)	No (n = 293)	*p*-value
Gender, n (%)					
	Male	198 (52.0)	52 (59.1)	146 (49.8)	0.127
	Female	183 (48.0)	36 (40.9)	147 (50.2)	
Age, year		65.7 (9.3)	67.0 (10.3)	65.3 (8.99)	0.122
Diabetes duration, year		6 (2–15)	9 (2.5–18)	6 (2–13)	0.048
BMI, kg/m^2		25.64 (4.36)	25.45 (4.60)	25.70 (4.30)	0.640
WHR		0.91 (0.07)	0.93 (0.07)	0.91 (0.07)	0.066
HbA1c, %		7.19 (0.99)	7.32 (1.15)	7.16 (0.94)	0.181
Systolic BP, mmHg		132.6 (12.15)	133.0 (13.24)	132.4 (11.83)	0.723
Diastolic BP, mmHg		78.4 (6.70)	78.1 (7.13)	78.5 (6.58)	0.556
Triglycerides, mmol/L		1.3 (1.0 – 1.9)	1.4 (1.0 – 2.0)	1.3 (1.0 – 1.9)	0.492
Cholesterol, mmol/L		5.04 (0.90)	4.97 (0.90)	5.06 (0.90)	0.468
LDL cholesterol, mmol/L		3.05 (0.88)	2.92 (0.94)	3.09 (0.87)	0.129
HDL cholesterol, mmol/L		1.23 (0.35)	1.20 (0.34)	1.24 (0.35)	0.391
ACR, mg/g		22 (8.9 – 61.2)	179.9 (47.1 – 763.9)	14.5 (7.2 –31.5)	0.249
eGFR, $ml/min/1.73\ m^2$		81.9 (25.2)	71.4 (27.8)	80.0 (23.51)	< 0.001

Data are presented as mean (SD) or median (interquartile range).

Supplementary Table 3. Characteristics of normoalbuminuric Chinese Type 2 diabetic patients according to the urinary presence of the 25 kDa immuno-reactive nephrin fragment

		Total (n = 228)	Yes (n = 12)	No (n = 216)	*p*-value
Gender (%)					
	Male	114 (50.0)	7 (58.3)	107 (49.5)	0.553
	Female	114 (40.0)	5 (41.7)	109 (50.5)	
Age, year		64.9 (9.2)	67.1 (10.5)	64.8 (9.2)	0.403
Diabetes duration, yr		5 (2 – 12)	3.5 (2 – 10)	5.5 (3 – 13)	0.432
BMI, kg/m^2		25.26 (3.97)	24.29 (4.75)	25.32 (3.92)	0.385
WHR		0.91 (0.07)	0.91 (0.06)	0.91 (0.07)	0.827
HbA1c, %		7.14 (0.94)	7.07 (1.35)	7.14 (0.91)	0.792
Systolic BP, mmHg		131.7 (11.07)	131.7 (12.29)	131.7 (11.0)	0.984
Diastolic BP, mmHg		78.4 (6.55)	76.83 (7.92)	78.47 (6.48)	0.403
Triglycerides, mmol/L		1.2 (0.9 – 1.7)	1.0 (0.6 – 1.5)	1.2 (0.9 – 1.7)	0.146
Cholesterol, mmol/L		5.02 (0.86)	4.62 (0.61)	5.05 (0.87)	0.108
LDL cholesterol, mmol/L		3.09 (0.86)	2.84 (0.55)	3.10 (0.87)	0.312
HDL cholesterol, mmol/L		1.25 (0.35)	1.27 (0.22)	1.25 (0.36)	0.839
ACR, mg/g		10.5 (6.0 – 16.9)	15.8 (11.2 – 19.5)	10.3 (5.9 – 16.9)	0.077
eGFR, $ml/min/1.73\ m^2$		85.5 (22.5)	65.6 (25.9)	86.6 (21.9)	0.003

Data are presented as mean (SD) or median (interquartile range).

CLAIMS

What is claimed is:

1. A method of detecting reduced renal function in a mammalian subject comprising detecting one or more nephrin degradation products in a urine sample from the subject, which indicates reduced renal function in the subject.

2. The method of Claim 1, wherein the mammal is a human.

3. The method of Claim 1, wherein the mammal is normoalbuminuric.

4. The method of Claim 1, wherein the one or more nephrin degradation products has an apparent molecular weight of about 25 kDa, 50 kDa, 60 kDa or 75 kDa.

5. The method of Claim 4, wherein the one or more nephrin degradation products has an apparent molecular weight of about 25 kDa.

6. The method of Claim 1, wherein the one or more nephrin degradation products are detected using an antibody.

7. The method of Claim 6, wherein the antibody is a monoclonal antibody.

8. The method of Claim 1, wherein the mammal exhibits a decline in eGFR of at least 1.0 ml/min/1.73 m^2.

9. The method of Claim 1, wherein the mammal has or is at increased risk of developing type 2 diabetes, wherein, optionally, a subject with type 2 diabetes has been diagnosed as diabetic for a year or less.

10. The method of any one of Claims 1, wherein the one or more nephrin degradation products are detected by ELISA, Western Blotting, RIA, HPLC, SPR, nucleic acid or protein aptamers, SAT, peptide sequencing, or MS/MS.

11. The method of Claim 1, wherein the nephrin degradation products are detected in a cell free fraction of the urine sample.

12. The method of Claim 1, further comprising administering a suitable prophylaxis for reduced renal function, wherein the prophylaxis is one or more antagonists of the renin-angiotensin system (RAS).

13. A method of detecting reduced renal function in a human with type 2 diabetes comprising detecting a soluble nephrin degradation product with an apparent molecular weight of about 25 kDa, 50 kDa, 60 kDa or 75 kDa in a urine sample from the subject using an antibody specific for nephrin, wherein detection of one or more nephrin degradation products in the urine sample indicates reduced renal function in the subject.

14. The method of Claim 13, wherein the human is normoalbuminuric.

15. A kit for detecting reduced renal function in a mammal comprising an antibody that binds one or more nephrin degradation products and instructions for use.

16. The kit of Claim 15, wherein the kit further comprises one or more nephrin degradation products suitable for use as a positive control.

17. The kit of Claim 15, wherein the antibody that binds one or more nephrin degradation products is associated with an immunochromatographic device.

18. An antibody that binds one or more nephrin degradation products for detecting reduced renal function in a mammal with type 2 diabetes by urinalysis.

19. The antibody of Claim 18, wherein the mammal is a human.

20. The antibody of Claim 18, wherein the mammal is normoalbuminuric.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SG2011/000143

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl.

G01N 33/68 (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
WPIDS, MEDLINE, CAPLUS, JAPIO; KEYWORDS: NEPHRIN, NEPHROSIS, RENAL, KIDNEYS, DIABETES, NIDDM, FRAGMENT, BIOMARKER and like terms

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	PÄTÄRI A et al, "Nephrinuria in diabetic nephropathy of type 1 diabetes" Diabetes. (2003) Dec; Vol 52, No 12, p2969-74	
X	Figure 3, pages 2969-2972	1-8, 10-12, 15-20
Y	Abstract, figure 3	3-5, 13-14
	WO2000/077044 A1 (HOLTHÖFER H) 21 December 2000	
X	Pages 1, 6, 12-14, claims	1-2, 6-8, 9-12, 15-20
Y	Example 14, Pages 7, 15-16	3-5, 13-14
	US6969591 B2 (HARA) 29 November 2005	
X	Columns 3-4, claims	15, 17-20

[X] Further documents are listed in the continuation of Box C [X] See patent family annex

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
26 May 2011	31 MAY 2011
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. +61 2 6283 7999	Authorized officer **ROSS OSBORNE** AUSTRALIAN PATENT OFFICE (ISO 9001 Quality Certified Service) Telephone No : +61 2 6283 2404

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SG2011/000143

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WANG G et al, "Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker" European Journal of Endocrinology (2008) Vol 158 p 317–322 Abstract	8, 12
A	PÄTÄRI A, "A 100-kDa urinary protein is associated with insulin resistance in offspring of type 2 diabetic patients", Diabetologia (2005) Vol 48, No 9, p1844-50. Epub 8 July 2005 Abstract	
A	CHAUDHARY K. et al, "The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease", Curr Diab Rep (2010) Vol 10 p37-42 Whole document	
P,X	NG D.P. et al, "Nephrinuria associates with multiple renal traits in type 2 diabetes" Nephrol Dial Transplant (2010) Vol 0 pages 1–7, Epub ahead of print; 31 Dec 2010 Whole document.	1-20

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.
PCT/SG2011/000143

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member					
WO	0077044	AU	52253/00	CA	2374000	EP	1185556
US	6969591	AU	90309/01	EP	1336845	JP	2008122410
		US	2004058395	WO	0237099		

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

END OF ANNEX